+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ulcerative Colitis Market - Global Forecast 2026-2032- Product Image
Ulcerative Colitis Market - Global Forecast 2026-2032- Product Image
Sale

Ulcerative Colitis Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4985922
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Ulcerative Colitis Market is projected to reach USD 9.54 Billion in 2026. It is expected to continue growing at a CAGR of 8.41%, reaching USD 15.51 Billion by 2032.

Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon and rectum, with relapsing symptoms that can include bloody diarrhea, urgency, abdominal pain, fatigue, and anemia. The commercial landscape is expanding as diagnosis improves, biologic and small-molecule adoption rises, and treatment goals shift from symptom control toward endoscopic healing, steroid-free remission, and long-term prevention of colectomy.

Demand is supported by a well-documented rise in inflammatory bowel disease prevalence across industrialized markets and accelerating incidence in newly industrialized economies. The U.S. Centers for Disease Control and Prevention has reported millions of U.S. adults living with inflammatory bowel disease, while peer-reviewed epidemiology literature consistently shows high prevalence in North America and Europe and fast growth in Asia-Pacific, the Middle East, and Latin America.

For industry leaders, the ulcerative colitis market is defined by innovation density. Anti-TNF agents, integrin inhibitors, IL-12/23 and IL-23 pathway therapies, Janus kinase inhibitors, and sphingosine-1-phosphate receptor modulators are reshaping treatment sequencing, payer negotiations, and patient expectations. Competitive advantage increasingly depends on differentiated efficacy, safety, convenience, affordability, real-world evidence, and digital support across the patient journey.

Transformative Shifts in the Ulcerative Colitis Landscape

The ulcerative colitis landscape is undergoing a decisive shift from step-up therapy to more personalized, treat-to-target care. Gastroenterology guidelines increasingly emphasize objective disease assessment through endoscopy, biomarkers such as fecal calprotectin and C-reactive protein, and validated symptom scores. This is changing how therapies are selected, monitored, and switched.

Recent regulatory activity has expanded treatment choice. Approvals for advanced therapies, including sphingosine-1-phosphate receptor modulators, selective Janus kinase inhibitors, IL-23 pathway therapies, and additional oral small molecules, have increased competition beyond traditional anti-TNF biologics. At the same time, biosimilars for established biologics are creating pricing pressure, widening access, and encouraging earlier use of advanced therapy in eligible patients.

Care delivery is also transforming. Home-based administration, specialty pharmacy coordination, remote monitoring, and digital adherence tools are reducing friction in chronic disease management. The most successful market participants are aligning clinical outcomes with patient convenience, payer evidence needs, and health-system capacity constraints.

Cumulative Impact of Artificial Intelligence on Ulcerative Colitis

Artificial intelligence is becoming a cumulative force across ulcerative colitis research, diagnosis, treatment optimization, and commercialization. In clinical development, AI-enabled analytics can screen electronic health records, identify eligible trial populations, simulate protocol feasibility, and improve site selection. This matters in ulcerative colitis, where heterogeneous disease severity, prior advanced therapy exposure, and fluctuating disease activity complicate recruitment.

In clinical practice, computer-aided endoscopy and image analytics are being evaluated to support consistent assessment of mucosal inflammation. AI-based interpretation of colonoscopy and histology images may help standardize scoring systems, reduce inter-reader variability, and support treat-to-target decisions when validated and integrated responsibly.

The commercial impact is also significant. Natural language processing can extract real-world evidence from clinical notes, payer data, and registries, while predictive models can support adherence programs and risk stratification. Industry leaders must balance these benefits with rigorous validation, bias monitoring, privacy protection, cybersecurity readiness, and transparent governance to meet regulatory and clinician expectations.

Key Regional Insights for Ulcerative Colitis

North America remains one of the most mature ulcerative colitis markets, supported by high inflammatory bowel disease prevalence, advanced gastroenterology infrastructure, extensive biologic use, and established reimbursement pathways for specialty medicines. The United States drives regional innovation through clinical trials, academic IBD centers, regulatory approvals, and real-world evidence generation, while Canada benefits from structured public and private reimbursement systems, provincial access decisions, and active specialist networks.

Europe has a high disease burden and a sophisticated access environment shaped by regional regulators, national health technology assessment bodies, and cost-effectiveness requirements. Germany, France, Italy, Spain, and the United Kingdom are central markets, with biosimilar adoption and treatment guidelines influencing prescribing behavior. The European focus on value-based healthcare increases the importance of comparative effectiveness, long-term safety data, patient-reported outcomes, and evidence of steroid-free remission.

Asia-Pacific is the fastest-changing region as ulcerative colitis incidence rises in China, India, Japan, South Korea, Australia, and ASEAN economies. Urbanization, dietary changes, improved diagnostic capacity, and expanding insurance coverage are contributing to broader treatment adoption. Latin America, led by Brazil and Mexico, is gaining momentum as specialty care access improves, though affordability and public-sector procurement remain key constraints. The Middle East, especially Gulf countries, is investing in tertiary care, digestive disease centers, and access to biologics and oral advanced therapies, while Africa remains earlier in market development with substantial unmet needs in diagnosis, specialist availability, endoscopy capacity, and therapy affordability.

Key Group Insights Across G7, EU, BRICS, ASEAN, GCC, and NATO

The G7 represents the highest-intensity cluster for ulcerative colitis commercialization because it combines high diagnosis rates, advanced prescribing, payer sophistication, and dense clinical trial activity. The United States, Canada, Japan, Germany, France, Italy, and the United Kingdom are central to launch sequencing, health-economic evidence generation, guideline influence, and post-marketing surveillance.

The European Union is strategically important because reimbursement decisions are closely tied to comparative clinical benefit, budget impact, biosimilar competition, and real-world outcomes. EU markets also lead biosimilar penetration in many therapeutic classes, making lifecycle management, differentiation, and evidence communication essential. NATO countries overlap with many high-income markets where resilient medicine supply chains, domestic manufacturing capacity, and health-security planning increasingly influence procurement and continuity of care for chronic immune-mediated diseases.

BRICS economies are becoming long-term growth engines for ulcerative colitis care. China and India are expanding diagnosis and access, Brazil supports Latin American demand, and South Africa represents a gateway for selected African markets, while Russia maintains a substantial patient base despite access and geopolitical complexities. ASEAN is at an earlier but rising stage of adoption as gastroenterology infrastructure improves in markets such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is a premium access cluster with strong hospital investment, high use of imported specialty medicines, and increasing focus on local healthcare transformation, specialty centers, and chronic disease management.

Key Country Insights for Ulcerative Colitis

The United States is the largest single-country opportunity by treatment intensity due to high inflammatory bowel disease prevalence, rapid uptake of approved therapies, robust specialty pharmacy channels, and a competitive payer environment. Canada offers a smaller but well-structured market where public formularies, private insurance, and provincial decisions shape access. Mexico and Brazil are key Latin American markets, with private-sector adoption outpacing broader public access and public procurement influencing therapy availability.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high clinical expertise with disciplined reimbursement review. Germany often provides early post-approval access under European pathways, while the United Kingdom places strong emphasis on cost-effectiveness through health technology assessment. France, Italy, and Spain require strong evidence packages, regional access planning, and alignment with national prescribing guidance. Russia remains a relevant market by population size, but access is affected by procurement structures, reimbursement variability, and geopolitical risk.

China and India are high-potential markets due to large populations, rising diagnosis, and expanding specialty care, though affordability and uneven access remain important. Japan has a mature gastroenterology market with established use of advanced therapies, rigorous regulatory standards, and strong physician engagement in inflammatory bowel disease care. South Korea and Australia demonstrate advanced treatment adoption, high-quality clinical practice, reimbursement pathways for eligible patients, and active participation in global trials, making them important reference markets in Asia-Pacific.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated evidence that demonstrates durable clinical remission, mucosal healing, steroid-sparing benefit, safety, and quality-of-life improvement in real-world ulcerative colitis populations. Comparative studies, registry evidence, patient-reported outcomes, and payer-relevant endpoints are increasingly important as more advanced therapies compete for similar patient segments.

Market access teams should prepare region-specific value dossiers that address biosimilar pressure, budget impact, safety monitoring, and treatment sequencing. Patient support programs should reduce abandonment through education, prior authorization support, adherence tracking, injection or infusion coordination, and collaboration among gastroenterologists, nurses, specialty pharmacies, and payers.

Organizations should invest in precision medicine, biomarker strategies, and AI-enabled evidence generation while maintaining strong governance. Partnerships with IBD centers, digital health providers, and patient advocacy organizations can improve recruitment, adherence, and outcomes. In emerging markets, phased access models, local partnerships, clinician education, and affordability strategies are essential to sustainable expansion.

Research Methodology

This executive summary is developed using a secondary research methodology aligned with market intelligence best practices. Inputs include publicly available regulatory approvals, clinical guideline trends, epidemiology findings, peer-reviewed inflammatory bowel disease literature, government health sources, health technology assessment signals, and published evidence on specialty medicine access.

The analysis emphasizes verified evidence rather than speculative estimates. Regional, group, and country insights are synthesized from documented differences in disease burden, healthcare infrastructure, reimbursement systems, regulatory environments, clinical trial concentration, biosimilar adoption, and specialty medicine access.

Findings are triangulated across clinical, commercial, and policy dimensions to support an evidence-based interpretation. The methodology favors durable market drivers, observable treatment shifts, and validated healthcare trends over short-term promotional claims or unverified projections.

Conclusion

The ulcerative colitis market is entering a more competitive and outcomes-driven era. Rising disease recognition, expanding advanced therapy options, biosimilar competition, and the adoption of treat-to-target care are changing how patients are diagnosed, treated, and monitored.

North America and Europe remain the most mature markets, while Asia-Pacific, Latin America, the Middle East, and selected African countries represent important growth frontiers. Across all regions, success will depend on differentiated clinical value, access strategy, real-world evidence, patient-centric support, and responsible use of artificial intelligence.

Organizations that combine scientific innovation with affordability, evidence transparency, and scalable care models will be best positioned to lead in ulcerative colitis treatment and long-term inflammatory bowel disease management.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Ulcerative Colitis Market, by Therapy Type
7.1. Introduction
7.2. Aminosalicylates
7.2.1. Mesalamine
7.2.2. Sulfasalazine
7.3. Biologics
7.3.1. Anti Integrins
7.3.2. IL Inhibitors
7.3.3. TNF Inhibitors
7.3.3.1. Infliximab
7.3.3.2. Adalimumab
7.3.3.3. Golimumab
7.4. Corticosteroids
7.4.1. Prednisone
7.4.2. Budesonide
7.4.3. Hydrocortisone
7.5. Immunomodulators
7.5.1. Azathioprine
7.5.2. 6-Mercaptopurine
7.5.3. Methotrexate
7.6. Small Molecule Drugs
7.6.1. Tofacitinib
7.6.2. Upadacitinib
7.7. Surgery
8. Ulcerative Colitis Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.2.1. Intravenous
8.2.2. Subcutaneous
8.3. Oral
8.4. Topical
9. Ulcerative Colitis Market, by Type
9.1. Introduction
9.2. Ulcerative Proctitis
9.3. Proctosigmoiditis
9.4. Left-Sided Colitis
9.5. Extensive Colitis
10. Ulcerative Colitis Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line & Beyond
11. Ulcerative Colitis Market, by Disease Severity
11.1. Introduction
11.2. Mild
11.3. Moderate
11.4. Severe
12. Ulcerative Colitis Market, by Patient Type
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Ulcerative Colitis Market, by Distribution Channel
13.1. Introduction
13.2. Offline Pharmacy
13.3. Online Pharmacy
14. Ulcerative Colitis Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Ulcerative Colitis Market, by Group
15.1. NATO
15.2. G7
15.3. European Union
15.4. BRICS
15.5. ASEAN
15.6. GCC
16. Ulcerative Colitis Market, by Country
16.1. United States
16.2. China
16.3. Germany
16.4. Japan
16.5. India
16.6. United Kingdom
16.7. France
16.8. Canada
16.9. Italy
16.10. Australia
16.11. Brazil
16.12. Russia
16.13. Mexico
16.14. South Korea
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc.
18.2. Abivax SA
18.3. Ajinomoto Pharmaceuticals Co., Ltd.
18.4. Amgen Inc.
18.5. Apotex Inc.
18.6. AstraZeneca plc
18.7. Bausch Health Companies Inc.
18.8. Biocon Limited
18.9. Boehringer Ingelheim GmbH
18.10. Bristol-Myers Squibb Company
18.11. Celltrion, Inc.
18.12. Dr. Falk Pharma GmbH
18.13. EA Pharma Co., Ltd.
18.14. Eli Lilly and Company
18.15. F. Hoffmann-La Roche AG
18.16. Ferring International Center S.A.
18.17. Fresenius Kabi AG
18.18. Galapagos NV
18.19. Gilead Sciences Inc.
18.20. Janssen Biotech, Inc. by Johnson & Johnson
18.21. Merck & Co., Inc.
18.22. Novartis AG
18.23. Pfizer Inc.
18.24. Samsung Bioepis Co., Ltd.
18.25. Sandoz International GmbH
18.26. Sanofi S.A.
18.27. Sun Pharmaceutical Industries Ltd.
18.28. Takeda Pharmaceutical Company Limited
18.29. Viatris Inc.
18.30. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL ULCERATIVE COLITIS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ULCERATIVE COLITIS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ULCERATIVE COLITIS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ULCERATIVE COLITIS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL ULCERATIVE COLITIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ULCERATIVE COLITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL AMINOSALICYLATES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL AMINOSALICYLATES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL AMINOSALICYLATES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL MESALAMINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL MESALAMINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL MESALAMINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SULFASALAZINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SULFASALAZINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SULFASALAZINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ANTI INTEGRINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ANTI INTEGRINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ANTI INTEGRINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL IL INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL IL INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL IL INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL TNF INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL INFLIXIMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL INFLIXIMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL INFLIXIMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ADALIMUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ADALIMUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ADALIMUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL GOLIMUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GOLIMUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GOLIMUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PREDNISONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PREDNISONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PREDNISONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL BUDESONIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL BUDESONIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL BUDESONIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL HYDROCORTISONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL HYDROCORTISONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL HYDROCORTISONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL AZATHIOPRINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL AZATHIOPRINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL AZATHIOPRINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL 6-MERCAPTOPURINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL 6-MERCAPTOPURINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL 6-MERCAPTOPURINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL METHOTREXATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL METHOTREXATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL METHOTREXATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL TOFACITINIB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL TOFACITINIB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TOFACITINIB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL UPADACITINIB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL UPADACITINIB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL UPADACITINIB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL SURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL SURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ULCERATIVE PROCTITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL ULCERATIVE PROCTITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ULCERATIVE PROCTITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PROCTOSIGMOIDITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PROCTOSIGMOIDITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL PROCTOSIGMOIDITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL LEFT-SIDED COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL LEFT-SIDED COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL LEFT-SIDED COLITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL EXTENSIVE COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL EXTENSIVE COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL EXTENSIVE COLITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL MILD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL MILD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL MILD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL MODERATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL MODERATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL MODERATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL SEVERE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL OFFLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 149. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 151. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 152. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 153. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 154. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 155. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 156. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 157. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 158. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 159. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 160. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 161. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 162. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 163. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 169. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 170. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 171. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 172. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 173. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 174. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 175. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 176. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 177. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 178. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 182. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 183. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 184. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 185. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 186. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 187. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 188. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 189. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 190. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 191. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 192. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 193. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 194. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 195. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 196. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 197. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 198. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 199. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 200. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 201. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 202. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 203. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 204. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 205. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 206. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 207. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 208. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 212. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 213. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 214. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 215. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 216. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 217. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 219. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 220. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 221. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 222. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 223. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 224. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 225. NATO ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 226. NATO ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 227. NATO ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 228. NATO ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 229. NATO ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 230. NATO ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 231. NATO ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 232. NATO ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 233. NATO ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 234. NATO ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 235. NATO ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 236. NATO ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 237. NATO ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 238. NATO ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 239. NATO ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 240. G7 ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 241. G7 ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 242. G7 ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 243. G7 ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 244. G7 ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 245. G7 ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 246. G7 ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 247. G7 ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 248. G7 ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 249. G7 ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 250. G7 ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 251. G7 ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 252. G7 ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 253. G7 ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 254. G7 ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. BRICS ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 271. BRICS ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 272. BRICS ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 273. BRICS ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 274. BRICS ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 275. BRICS ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 276. BRICS ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 277. BRICS ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 278. BRICS ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 279. BRICS ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 280. BRICS ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 281. BRICS ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 282. BRICS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 283. BRICS ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 284. BRICS ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 286. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 287. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 288. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 289. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 290. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 291. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 292. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 293. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 294. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 295. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 296. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 297. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 298. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 299. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 300. GCC ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 301. GCC ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 302. GCC ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 303. GCC ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 304. GCC ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 305. GCC ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 306. GCC ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 307. GCC ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 308. GCC ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 309. GCC ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 310. GCC ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 311. GCC ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 312. GCC ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 313. GCC ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 314. GCC ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 315. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 316. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 317. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 318. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 319. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 321. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 322. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 323. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 324. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 325. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 326. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 327. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 328. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 329. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 330. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 331. CHINA ULCERATIVE COLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 332. CHINA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 333. CHINA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 334. CHINA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 335. CHINA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 336. CHINA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 337. CHINA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 338. CHINA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 339. CHINA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 340. CHINA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 341. CHINA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 342. CHINA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 343. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 344. CHINA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 345. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 346. GERMANY ULCERATIVE COLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 347. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 348. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 349. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 350. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 351. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 352. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 353. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 354. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 355. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 356. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 357. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 358. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 359. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 360. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 361. JAPAN ULCERATIVE COLITIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 362. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 363. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2017-2032 (USD MILLION)
TABLE 364. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 365. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2017-2032 (USD MILLION)
TABLE 366. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2017-2032 (USD MILLION)
TABLE 367. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2017-2032 (USD MILLION)
TABLE 368. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2017-2032 (USD MILLION)
TABLE 369. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD

Companies Mentioned

  • AbbVie Inc.
  • Abivax SA
  • Ajinomoto Pharmaceuticals Co., Ltd.
  • Amgen Inc.
  • Apotex Inc.
  • AstraZeneca plc
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celltrion, Inc.
  • Dr. Falk Pharma GmbH
  • EA Pharma Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann‑La Roche AG
  • Ferring International Center S.A.
  • Fresenius Kabi AG
  • Galapagos NV
  • Gilead Sciences Inc.
  • Janssen Biotech, Inc. by Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 9.54 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.51 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Ulcerative Colitis Therapeutics - Global Strategic Business Report - Product Image

Ulcerative Colitis Therapeutics - Global Strategic Business Report

  • Report
  • 208 Pages
  • Global
From
Ulcerative Colitis Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035) - Product Image

Ulcerative Colitis Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

  • Report
  • 400 Pages
  • Global
From
Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2026-2034 - Product Image

Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2026-2034

  • Report
  • 150 Pages
  • Global
From
Ulcerative Colitis Market Report 2026 - Product Image

Ulcerative Colitis Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Balsalazide Market - Global Forecast 2026-2032 - Product Image

Balsalazide Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From

About the Ulcerative Colitis Drug Market

The Ulcerative Colitis Drug market is a subset of the Gastrointestinal Drugs market, which includes medications used to treat a variety of gastrointestinal disorders. Ulcerative Colitis Drugs are used to treat the chronic inflammatory bowel disease of the same name. These drugs are typically administered orally or intravenously, and can be used to reduce inflammation, improve symptoms, and induce and maintain remission. Commonly prescribed Ulcerative Colitis Drugs include aminosalicylates, corticosteroids, immunomodulators, and biologics. The Ulcerative Colitis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Pfizer, Takeda, Janssen, and UCB. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.